Department of Vascular and Endovascular Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
J Vasc Access. 2024 Mar;25(2):369-389. doi: 10.1177/11297298221102875. Epub 2022 Jun 16.
It is challenging for a surgeon to determine the appropriate vascular access for hemodialysis patients whose cephalic vein is usually inaccessible. The purpose of the study is to compare the complications and patency rates between transposed arteriovenous fistulas (tAVF) and arteriovenous graft (AVG) for the hemodialysis patients. Studies were recruited from PubMed, Cochrane library, EMBASE, the web of science databases, and reviewing reference lists of related studies from the inception dates to September 2, 2021. Statistical analyses were conducted using the statistical tool Review Manager version5.3 (Cochrane Collaboration, London, UK). > 50% was defined as a high degree of heterogeneity, and then a random-effects model was used. Otherwise, the fixed-effects model was used. Odds ratio with its 95% confidence interval (95% CI) was used. Thirty-three trials (26 retrospective studies, four randomized controlled trials, two prospective trials, and one controlled-comparative study) with 6430 enrolled participants were identified in our analysis. The results showed that tAVF was accompanied with lower thrombosis rate (103/1184 (8.69%) vs 257/1367 (18.80%); = 45%; 95% CI, 0.34 (0.26, 0.45)) and infection rate (43/2031 (2.12%) vs 180/2147 (8.38%); = 0%; 95% CI, 0.20 (0.14, 0.30)) than arteriovenous graft. The significantly better primary patency rates, secondary patency rates, and primary assisted patency rates during follow-up were found in tAVF. However, the failure rate and the prevalence of hematoma were significantly lower in AVG group. No evidence showed the rate of overall mortality, steal syndrome, and aneurysm reduced in tAVF. Our results showed that tAVF is a promising vascular access technique for hemodialysis patients whose cephalic vein is inaccessible. Our data showed that tAVF has less thrombosis, infection risk, and better patency rates when compared with AVG. However, more attentions need to be paid to transposed arteriovenous fistulas maturation and hematoma.
对于头静脉通常无法触及的血液透析患者,外科医生确定合适的血管通路具有挑战性。本研究的目的是比较转位动静脉瘘(tAVF)和动静脉移植物(AVG)在血液透析患者中的并发症和通畅率。研究从 PubMed、Cochrane 图书馆、EMBASE、Web of Science 数据库中招募,并从相关研究的参考文献列表中进行回顾,检索时间截至 2021 年 9 月 2 日。使用统计工具 Review Manager version5.3(Cochrane 协作组,英国伦敦)进行统计分析。 > 50% 定义为高度异质性,然后使用随机效应模型。否则,使用固定效应模型。使用比值比及其 95%置信区间(95%CI)。我们的分析确定了 33 项试验(26 项回顾性研究、4 项随机对照试验、2 项前瞻性试验和 1 项对照比较研究),共纳入 6430 名参与者。结果表明,tAVF 血栓形成率较低(103/1184(8.69%)与 257/1367(18.80%); = 45%;95%CI,0.34(0.26,0.45))和感染率(43/2031(2.12%)与 180/2147(8.38%); = 0%;95%CI,0.20(0.14,0.30))低于动静脉移植物。在随访期间,tAVF 的主要通畅率、次要通畅率和主要辅助通畅率显著更高。然而,AVG 组的失败率和血肿发生率明显较低。没有证据表明 tAVF 降低了总死亡率、盗血综合征和动脉瘤的发生率。我们的结果表明,对于头静脉无法触及的血液透析患者,tAVF 是一种很有前途的血管通路技术。我们的数据显示,与 AVG 相比,tAVF 血栓形成、感染风险较低,通畅率较高。然而,需要更多地关注转位动静脉瘘的成熟和血肿。